Practical Insights into Risk-Adapted Implementation of Perioperative FLOT for Resectable Gastroesophageal Adenocarcinoma
Background : Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is expected to become an increasingly important standard approach for locally advanced gastroesophageal adenocarcinoma (GEA), including in Asia. However, practical management strategies for elderly or vulnerable patients in Asia remain unclear. Methods: We retrospectively reviewed patients with GEA who received perioperative FLOT through January 2025. Patients were categorized into three age groups: <60, 60–74, and ≥75 years. Results: Among 147 patients, 19.0%, 51.7%, and 29.3% were aged <60, 60–74, and ≥75 years, respectively. Initial dose reduction increased with age (0%, 10.5%, and 67.4%, respectively), whereas neoadjuvant completion rates and pathological complete response rates were comparable across groups. In contrast, initiation and completion of adjuvant FLOT declined with age. The most common grade ≥3 adverse events were neutropenia (35.4%), anorexia (7.5%), and febrile neutropenia (5.4%), without apparent age-related increases. Intravenous fluid support was most frequently required during cycle 1 and increased with age. Prophylactic pegylated granulocyte colony-stimulating factor was associated with lower rates of severe neutropenia and febrile neutropenia, while prophylactic olanzapine was associated with lower anorexia rates. Conclusions: Individualized dose modification and proactive supportive care may facilitate safe implementation of perioperative FLOT, particularly for elderly or vulnerable patients. These findings may help optimize the real-world use of FLOT-based perioperative strategies in Asia.
Authors
- Takahiro Kinoshita (ORCID: https://orcid.org/0000-0001-7365-8733)
- Taisuke Hosokai
- Akihito Kawazoe
- Kohei Shitara (ORCID: https://orcid.org/0000-0001-5196-3630)
- Kyosuke Seguchi (ORCID: https://orcid.org/0000-0002-8646-3094)
- Yuki Matsubara (ORCID: https://orcid.org/0000-0003-4009-0015)
- Takeo Fujita (ORCID: https://orcid.org/0000-0002-6098-9813)
- Amane Jubashi (ORCID: https://orcid.org/0000-0003-1816-476X)
- Daisuke Kotani (ORCID: https://orcid.org/0000-0002-4196-555X)
- Masahiro Yura (ORCID: https://orcid.org/0000-0001-7102-9212)
- Hideaki Bando (ORCID: https://orcid.org/0000-0001-5041-2765)
- Izuma Nakayama (ORCID: https://orcid.org/0000-0003-4987-1934)
- Yasutoshi Kuboki (ORCID: https://orcid.org/0000-0003-3675-953X)
- Saori Mishima (ORCID: https://orcid.org/0000-0002-5922-1487)
- Yu Miyashita (ORCID: https://orcid.org/0000-0001-8278-4088)
- Takashi Kojima (ORCID: https://orcid.org/0000-0002-2554-8334)
- Mashiro Okunaka (ORCID: https://orcid.org/0000-0001-8031-818X)
- Mitsumasa Yoshida (ORCID: https://orcid.org/0000-0001-9238-2437)
- Kazuma Sato (ORCID: https://orcid.org/0000-0003-4653-4772)
- Kazumasa Yamamoto (ORCID: https://orcid.org/0009-0005-4085-0741)
- Rika Uchino
- T. Ogura
- Dai Okemoto
- Tadayoshi Hashimoto
Institutions
- National Cancer Center Hospital East (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11570663/v1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- preprint